Literature DB >> 9010237

Loss of heterozygosity on murine chromosome 6 in two-stage carcinogenesis: evidence for a conserved tumor suppressor gene.

J C Zenklusen1, L C Hodges, C J Conti.   

Abstract

We have recently demonstrated that loss of heterozygosity (LOH) at 7q31 is frequent in many kinds of human primary tumors and that introducing a single human chromosome (hchr) 7 into a murine squamous cell carcinoma (SCC)-derived cell line suppresses the malignant phenotype. To investigate whether the putative tumor suppressor gene on hchr 7 is conserved in mice, we studied LOH on mouse chromosome (mchr) 6 in chemically induced SCCs in (C57BL x DBA2) F1 (B6D2F1) females. LOH analysis was performed by polymerase chain reaction amplification of 17 (CA)n microsatellite repeats in mchr 6 A1-C3. As expected, all the B6D2F1-derived tumors were informative for all the locus assayed. The highest percentage of LOH in the hchr 7q-homologous segment was found at D6Mit50 (60.0%) and the other markers in this segment had LOH incidences normally distributed around the peak. The high incidence of LOH in the tumors studied suggests that a tumor suppressor gene relevant to the development of epithelial cancers is present on mchr 6 A2. As this segment is homologous with hchr 7q31, these data suggest that the putative tumor suppressor gene is conserved in the two species and explains the suppression of tumorigenicity when a single hchr 7 is introduced to a murine SCC cell line.

Entities:  

Mesh:

Year:  1997        PMID: 9010237     DOI: 10.1038/sj.onc.1200806

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Method to Study Skin Cancer: Two-Stage Chemically Induced Carcinogenesis in Mouse Skin.

Authors:  Andrei N Mardaryev
Journal:  Methods Mol Biol       Date:  2020

2.  Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade.

Authors:  F Galbiati; D Volonte; J A Engelman; G Watanabe; R Burk; R G Pestell; M P Lisanti
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.